Alendronate Sodium Tablet
Product Images NDC 50090-4692

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-4692). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 01

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 02

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 03

This text provides information on the results of an osteoporosis treatment study in postmenopausal women. Specifically, it shows an increase in bone mineral density (BMD) after three years of treatment with Alendronate Sodium 10 mg/day. The table shows BMD measurements for different skeletal sites, including the lumbar spine, femoral neck, and trochanter.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 04

Osteoporosis Treatment Studies in Postmenopausal women comparing the effect of taking Alendronate Sodium 10 mg/day versus placebo over time. The study measured the percent change in Bone Mineral Density (BMD) of the Lumbar Spine from the starting point. The study was conducted in both the US and multiple countries. The provided data shows a graph with axes labeled for time in months and BMD change from baseline in percentage. The graph consists of multiple lines representing different data points. No further information is available to provide more context.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 05

This appears to be a table with headings and subheadings related to studies on bone mineral density in postmenopausal women. Specifically, it shows data on the percentage change in BMD from baseline in two and three-year studies, with separate information on the lumbar spine, femoral neck, and total body. It also includes information on sodium intake.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 06

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 07

A study comparing the effects of Alendronate Sodium 40mg/day versus Placebo or Etidronate 400mg/day on serum alkaline phosphatase in Paget's disease of bone. The study included a total of 27 participants and displayed the serum levels of alkaline phosphatase over time (in months) for each treatment. Mean percentage changes from baseline were also reported. No further details were available for review.*

FDA Label Image

Label Image (Lbl500904692)

This appears to be a label or tag for a medication package containing 4 tablets in a blister pack. It lists a product code as "irmu:'z No. 6050-0" and instructions to store at a location with the address "6810 7 OkGAEES."*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.